Vertex Pharmaceuticals (VRTX) Accounts Payables (2009 - 2026)

Vertex Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $489.3 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 9.96% year-over-year to $489.3 million; the TTM figure through Mar 2026 stood at $489.3 million (up 9.96% YoY), while the FY2025 annual figure was $461.7 million, up 11.79% from the prior year.
• Accounts Payables was $489.3 million for Q1 2026 at Vertex Pharmaceuticals, up from $461.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $489.3 million in Q1 2026 to a low of $126.9 million in Q3 2022.
• Historically, Accounts Payables has averaged $351.5 million across 5 years, with a median of $364.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 196.22% in 2023, then decreased 9.67% in 2024.
• A 5-year view of Accounts Payables shows it stood at $303.9 million in 2022, then gained by 20.07% to $364.9 million in 2023, then advanced by 13.18% to $413.0 million in 2024, then increased by 11.79% to $461.7 million in 2025, then climbed by 5.98% to $489.3 million in 2026.
• The last three Accounts Payables figures came in at $489.3 million (Q1 2026), $461.7 million (Q4 2025), and $420.3 million (Q3 2025), per Business Quant data.